Mycoplasma Testing Market by Product & Service (Assays, Kits, Reagents), Technique (NAT, ELISA, Staining), Application (Cell Line, End of Production Testing), End User (Biopharmaceutical, Cell Banks, CROs), Region - Global Forecast to 2025

マイコプラズマ検査の世界市場予測(~2025):製品・サービス別、技術別、用途別、エンドユーザー別、地域別

◆タイトル:Mycoplasma Testing Market by Product & Service (Assays, Kits, Reagents), Technique (NAT, ELISA, Staining), Application (Cell Line, End of Production Testing), End User (Biopharmaceutical, Cell Banks, CROs), Region - Global Forecast to 2025
◆商品コード:BT 3371
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年11月30日
◆ページ数:150
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥514,800見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥691,600見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥847,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社はマイコプラズマ検査の世界市場が2020年689百万ドルから2025年1,095百万ドルまで、年平均9.7%成長すると予想しています。本市場調査資料では、マイコプラズマ検査の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品・サービス別(アッセイ・キット・試薬、機器、サービス)分析、技術別(核酸増幅検査(NAT)、酵素免疫測定法(ELISA)、染色、その他)分析、用途別(細胞株検査、ウイルス検査、エンドオブプロダクション細胞(EPC)検査)分析、エンドユーザー別(製薬・バイオテクノロジー企業、医薬品開発業務受託機関(CRO)、学術・研究機関、細胞バンク・実験室)分析、地域別分析、競争状況、企業情報などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・マイコプラズマ検査の世界市場規模:製品・サービス別(アッセイ・キット・試薬、機器、サービス)
・マイコプラズマ検査の世界市場規模:技術別(核酸増幅検査(NAT)、酵素免疫測定法(ELISA)、染色、その他)
・マイコプラズマ検査の世界市場規模:用途別(細胞株検査、ウイルス検査、エンドオブプロダクション細胞(EPC)検査)
・マイコプラズマ検査の世界市場規模:エンドユーザー別(製薬・バイオテクノロジー企業、医薬品開発業務受託機関(CRO)、学術・研究機関、細胞バンク・実験室)
・マイコプラズマ検査の世界市場規模:地域別
・競争状況
・企業情報

“The global mycoplasma testing market size is valued at an estimated USD 689 million in 2020 and is projected to reach USD 1,095 million by 2025, at a CAGR of 9.7% during the forecast period.”
The global mycoplasma testing industry’s growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments.

“The assays, kits, & reagents segment accounted for the highest growth rate in the mycoplasma testing market, by product, during the forecast period.”
The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service. In 2019, the assays, kits, & reagents segment accounted for this market’s largest share. The frequent purchase of these consumables compared to instruments and the increasing use of kit-based techniques for mycoplasma testing are the important factors driving the growth of this market segment.

“Cell line testing segment accounted for the highest CAGR.”
Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing. In 2019, the cell line testing segment accounted for the largest share of this market. Factors such as the rapid growth in the biopharmaceutical industry and the increasing demand for monoclonal antibodies drive this market segment’s growth.

“Asia Pacific: The fastest-growing region mycoplasma testing market.”
The Asia Pacific mycoplasma testing market is estimated to grow at the highest CAGR during the forecast period. This can primarily be attributed to the expansion of key market players in emerging Asian countries, increasing expenditure on life science research in the region, and the increasing trend of pharmaceutical outsourcing to Asian countries such as India and China.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 – 35%
• By Designation: C-level – 30%, D-level – 20%, and Others – 50%
• By Region: North America – 36%, Europe – 25%, Asia Pacific – 27%, and Rest of the World – 12%

List of companies profiled in the report:
• Thermo Fisher Scientific, Inc. (US)
• Charles River Laboratories International, Inc. (US)
• Lonza Group Ltd. (Switzerland)
• Merck KGaA (Germany)
• Roche Diagnostics (Switzerland)
• American Type Culture Collection (US)
• Bionique Testing Laboratories, Inc. (US)
• InvivoGen (US)
• PromoCell GmbH (Germany),
• Biological Industries Israel Beit Haemek Ltd. (Israel)
• Creative Bioarray (US)
• Mycoplasma Experience (UK)
• Norgen Biotek Corp. (Canada)
• Agilent Technologies (US)
• Biotools B & M Labs, S.A. (Spain)
• Eurofins Scientific (Luxembourg)
• GeneCopoeia, Inc. (US)
• GenBio (Canada)
• Minerva Biolabs GmbH (Germany)
• Meridian Bioscience, Inc. (US)
• Sartorius AG (Germany)
• Savyon Diagnostics (Israel)
• Nelson Laboratories Fairfield, Inc. (US)
• Clongen Laboratories, LLC (US)
• ScienCell Research Laboratories, Inc. (Canada).

Research Coverage:
This report provides a detailed picture of the global mycoplasma testing market. It aims at estimating the size and future growth potential of the market across different segments, such as product, technique, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall mycoplasma testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and trends.

【レポートの目次】

1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
FIGURE 1 INCLUSIONS & EXCLUSIONS 25
1.2.1 MARKETS COVERED 26
FIGURE 2 MYCOPLASMA TESTING MARKET SEGMENTATION 26
1.2.2 YEARS CONSIDERED FOR THE STUDY 26
1.3 CURRENCY 27
1.4 LIMITATIONS 27
1.5 STAKEHOLDERS 27
1.6 SUMMARY OF CHANGES 27
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
FIGURE 3 RESEARCH DESIGN 29
2.1.1 SECONDARY DATA 30
2.1.1.1 Key data from secondary sources 30
2.1.2 PRIMARY DATA 31
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 31
2.2 MARKET SIZE ESTIMATION 32
2.2.1 BOTTOM-UP APPROACH 32
FIGURE 5 MYCOPLASMA TESTING MARKET: BOTTOM-UP APPROACH 32
2.2.2 TOP-DOWN APPROACH 33
FIGURE 6 MYCOPLASMA TESTING MARKET: TOP-DOWN APPROACH 33
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 34
FIGURE 7 DATA TRIANGULATION METHODOLOGY 34
2.4 ASSUMPTIONS FOR THE STUDY 35
3 EXECUTIVE SUMMARY 36
FIGURE 8 MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2020 VS. 2025 (USD MILLION) 36
FIGURE 9 MYCOPLASMA TESTING MARKET, BY APPLICATION,
2020 VS. 2025 (USD MILLION) 37
FIGURE 10 MYCOPLASMA TESTING MARKET, BY END USER,
2020 VS. 2025 (USD MILLION) 37
FIGURE 11 MYCOPLASMA TESTING MARKET, BY REGION, 2020 VS. 2025 (USD MILLION) 38

4 PREMIUM INSIGHTS 39
4.1 MYCOPLASMA TESTING MARKET OVERVIEW 39
FIGURE 12 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH 39
4.2 MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE,
2020 VS. 2025 (USD MILLION) 40
FIGURE 13 NAT ASSAYS, KITS, & REAGENTS SEGMENT TO COMMAND THE LARGEST MARKET SHARE IN 2019 40
4.3 MYCOPLASMA TESTING MARKET, BY TECHNIQUE, 2020 VS. 2025 40
FIGURE 14 GROWING ADOPTION OF NAT IN EMERGING ECONOMIES TO DRIVE MARKET GROWTH 40
4.4 MYCOPLASMA TESTING MARKET, BY REGION, 2020 VS. 2025 41
FIGURE 15 ASIA PACIFIC MARKET TO GROW AT THE HIGHEST CAGR DURING
THE FORECAST PERIOD 41
5 MARKET OVERVIEW 42
5.1 INTRODUCTION 42
5.2 MARKET DYNAMICS 42
FIGURE 16 MYCOPLASMA TESTING MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 42
5.2.1 DRIVERS 42
5.2.1.1 Growing concerns over cell culture contamination 42
5.2.1.2 Growth in pharmaceutical and biotechnology industries 43
TABLE 1 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2019–2020 43
5.2.1.3 Rising pharmaceutical R&D activities and investments 43
FIGURE 17 INCIDENCE OF THE TOP 10 FATAL CONDITIONS GLOBALLY, 2019 (%) 44
TABLE 2 RISING CANCER INCIDENCE, BY COUNTRY/REGION, 2018 VS. 2025 44
FIGURE 18 R&D SPENDING BY PHRMA MEMBER-COMPANIES,
2001–2019 (USD BILLION) 45
TABLE 3 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2018 45
5.2.2 OPPORTUNITIES 46
5.2.2.1 Globalization of clinical trials and R&D and harmonization of regulations resulting in increased outsourcing 46
5.2.2.2 Emerging economies 46
5.2.3 CHALLENGES 47
5.2.3.1 High degree of consolidation acts as an entry barrier for new entrants 47
5.3 IMPACT OF COVID-19 ON THE MYCOPLASMA TESTING MARKET 47
5.4 VALUE CHAIN ANALYSIS 48
FIGURE 19 VALUE CHAIN ANALYSIS OF THE MYCOPLASMA TESTING MARKET 48
FIGURE 20 RESTRAINTS IN THE VALUE CHAIN, BY STAGE 49
5.5 SUPPLY CHAIN ANALYSIS 49
FIGURE 21 SUPPLY CHAIN ANALYSIS OF THE MYCOPLASMA TESTING MARKET 50
5.6 ECOSYSTEM ANALYSIS 50
FIGURE 22 ECOSYSTEM ANALYSIS OF THE MYCOPLASMA TESTING MARKET 50
6 MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE 51
6.1 INTRODUCTION 52
TABLE 4 AVERAGE SELLING PRICE 52
TABLE 5 MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 52
6.2 ASSAYS, KITS, & REAGENTS 52
6.2.1 INCREASING ADOPTION OF NAT TO DRIVE MARKET GROWTH 52
TABLE 6 MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 53
TABLE 7 MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY REGION, 2018–2025 (USD MILLION) 53
6.2.2 NAT ASSAYS, KITS, & REAGENTS 54
TABLE 8 NAT ASSAYS, KITS, & REAGENTS MARKET, BY REGION,
2018–2025 (USD MILLION) 54
6.2.3 ENZYME-LINKED IMMUNOSORBENT ASSAYS, KITS, & REAGENTS 54
TABLE 9 ENZYME-LINKED IMMUNOSORBENT ASSAYS, KITS, & REAGENTS MARKET,
BY REGION, 2018–2025 (USD MILLION) 55
6.2.4 ELIMINATION KITS 55
TABLE 10 ELIMINATION KITS MARKET, BY REGION, 2018–2025 (USD MILLION) 55
6.2.5 STAINS 55
TABLE 11 MYCOPLASMA TESTING STAINS MARKET, BY REGION,
2018–2025 (USD MILLION) 56
6.2.6 OTHER ASSAYS, KITS, & REAGENTS 56
TABLE 12 OTHER ASSAYS, KITS, & REAGENTS MARKET, BY REGION,
2018–2025 (USD MILLION) 56
6.3 INSTRUMENTS 56
6.3.1 DEMAND FOR FULLY AUTOMATED INSTRUMENTS IS INCREASING IN RESEARCH APPLICATIONS 56
TABLE 13 MYCOPLASMA TESTING INSTRUMENTS MARKET, BY REGION,
2018–2025 (USD MILLION) 57
6.4 SERVICES 57
6.4.1 LACK OF INFRASTRUCTURE AND EXPERTISE HAVE DRIVEN RELIANCE ON SERVICE PROVIDERS 57
TABLE 14 MYCOPLASMA TESTING SERVICES MARKET, BY REGION,
2018–2025 (USD MILLION) 58
7 MYCOPLASMA TESTING MARKET, BY TECHNIQUE 59
7.1 INTRODUCTION 60
TABLE 15 MYCOPLASMA TESTING MARKET, BY TECHNIQUE,
2018–2025 (USD MILLION) 60
7.2 NUCLEIC ACID TESTING 60
7.2.1 NAT SEGMENT DOMINATED THE MARKET IN 2019 60
TABLE 16 NAT-BASED MYCOPLASMA TESTING MARKET, BY REGION,
2018–2025 (USD MILLION) 61

7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY 61
7.3.1 ELISA IS WIDELY USED FOR MYCOPLASMA DETECTION IN RESEARCH APPLICATIONS 61
TABLE 17 ELISA-BASED MYCOPLASMA TESTING MARKET, BY REGION,
2018–2025 (USD MILLION) 61
7.4 STAINING 62
7.4.1 STAINING OF CULTURES CAN PROVIDE RAPID RESULTS 62
TABLE 18 STAINING-BASED MYCOPLASMA TESTING MARKET, BY REGION,
2018–2025 (USD MILLION) 62
7.5 OTHER TECHNIQUES 62
TABLE 19 OTHER TECHNIQUES-BASED MYCOPLASMA TESTING MARKET, BY REGION, 2018–2025 (USD MILLION) 63
8 MYCOPLASMA TESTING MARKET, BY APPLICATION 64
8.1 INTRODUCTION 65
TABLE 20 MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 65
8.2 CELL LINE TESTING 65
8.2.1 RAPID GROWTH IN THE BIOPHARMACEUTICAL INDUSTRY TO DRIVE THE DEMAND FOR CELL LINE TESTING 65
TABLE 21 MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY REGION,
2018–2025 (USD MILLION) 66
TABLE 22 NORTH AMERICA: MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY COUNTRY, 2018–2025 (USD MILLION) 66
TABLE 23 EUROPE: MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING,
BY COUNTRY, 2018–2025 (USD MILLION) 67
TABLE 24 ASIA PACIFIC: MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING,
BY COUNTRY, 2018–2025 (USD MILLION) 67
8.3 VIRUS TESTING 67
8.3.1 RISING DEMAND FOR VACCINES TO DRIVE MARKET GROWTH 67
TABLE 25 KEY VIRUS TESTING PRODUCTS/SERVICES OFFERED BY MARKET PLAYERS 68
TABLE 26 MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY REGION,
2018–2025 (USD MILLION) 68
TABLE 27 NORTH AMERICA: MYCOPLASMA TESTING MARKET FOR VIRUS TESTING,
BY COUNTRY, 2018–2025 (USD MILLION) 69
TABLE 28 EUROPE: MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY COUNTRY, 2018–2025 (USD MILLION) 69
TABLE 29 ASIA PACIFIC: MYCOPLASMA TESTING MARKET FOR VIRUS TESTING,
BY COUNTRY, 2018–2025 (USD MILLION) 69
8.4 END-OF-PRODUCTION CELL TESTING 70
8.4.1 GROWING DEMAND FOR BIOLOGICS TO DRIVE MARKET GROWTH 70
TABLE 30 MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY REGION, 2018–2025 (USD MILLION) 70
TABLE 31 NORTH AMERICA: MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY COUNTRY, 2018–2025 (USD MILLION) 71
TABLE 32 EUROPE: MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY COUNTRY, 2018–2025 (USD MILLION) 71
TABLE 33 ASIA PACIFIC: MYCOPLASMA TESTING MARKET FOR END-OF-PRODUCTION CELL TESTING, BY COUNTRY, 2018–2025 (USD MILLION) 71
9 MYCOPLASMA TESTING MARKET, BY END USER 72
9.1 INTRODUCTION 73
TABLE 34 MYCOPLASMA TESTING MARKET, BY END USER, 2018–2025 (USD MILLION) 73
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 73
9.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES FORM THE LARGEST END-USER SEGMENT IN THE MYCOPLASMA TESTING MARKET 73
FIGURE 23 R&D INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY,
2012–2026 (USD BILLION) 74
TABLE 35 PHARMACEUTICAL PATENT GRANTS, 2017 VS. 2019, BY COUNTRY 74
TABLE 36 MYCOPLASMA TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018–2025 (USD MILLION) 75
9.3 CONTRACT RESEARCH ORGANIZATIONS 75
9.3.1 GROWTH IN OUTSOURCING TO DRIVE THE GROWTH OF THIS END-USER SEGMENT 75
TABLE 37 MYCOPLASMA TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018–2025 (USD MILLION) 76
9.4 ACADEMIC & RESEARCH INSTITUTES 76
9.4.1 ACADEMIC AND RESEARCH INSTITUTES PROVIDE VARIOUS MICROBIOLOGY TESTING SERVICES 76
TABLE 38 MYCOPLASMA TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018–2025 (USD MILLION) 77
9.5 CELL BANKS & LABORATORIES 77
9.5.1 IT IS ESTIMATED THAT ABOUT 5–30% OF THE WORLD’S CELL LINES ARE CONTAMINATED WITH MYCOPLASMAS 77
TABLE 39 MYCOPLASMA TESTING MARKET FOR CELL BANKS & LABORATORIES,
BY REGION, 2018–2025 (USD MILLION) 78
10 MYCOPLASMA TESTING MARKET, BY REGION 79
10.1 INTRODUCTION 80
TABLE 40 MYCOPLASMA TESTING MARKET, BY REGION, 2018–2025 (USD MILLION) 80
10.2 NORTH AMERICA 80
FIGURE 24 NORTH AMERICA: MYCOPLASMA TESTING MARKET SNAPSHOT 81
TABLE 41 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 81
TABLE 42 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 82
TABLE 43 NORTH AMERICA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 82
TABLE 44 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 82
TABLE 45 NORTH AMERICA: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 83

10.2.1 US 83
10.2.1.1 US is the largest market for mycoplasma testing products and services in North America 83
TABLE 46 US: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 84
TABLE 47 US: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 84
TABLE 48 US: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 84
TABLE 49 US: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 85
10.2.2 CANADA 85
10.2.2.1 Increasing pharma and biotech R&D investments to drive market growth 85
TABLE 50 CANADA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 86
TABLE 51 CANADA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET,
BY TYPE, 2018–2025 (USD MILLION) 86
TABLE 52 CANADA: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 86
TABLE 53 CANADA: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 87
10.3 EUROPE 87
TABLE 54 EUROPE: MYCOPLASMA TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 88
TABLE 55 EUROPE: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 88
TABLE 56 EUROPE: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET,
BY TYPE, 2018–2025 (USD MILLION) 88
TABLE 57 EUROPE: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 89
TABLE 58 EUROPE: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 89
10.3.1 GERMANY 89
10.3.1.1 Germany accounted for the largest share of the European market in 2019 89
TABLE 59 GERMANY: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION) 90
TABLE 60 GERMANY: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET,
BY TYPE, 2018–2025 (USD MILLION) 90
TABLE 61 GERMANY: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 90
TABLE 62 GERMANY: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 91
10.3.2 UK 91
10.3.2.1 Growth in the life science industry to support market growth in the UK 91
TABLE 63 UK: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 92
TABLE 64 UK: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 92
TABLE 65 UK: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 92
TABLE 66 UK: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 93
10.3.3 FRANCE 93
10.3.3.1 Increasing investments in life science R&D to support market growth in France 93
TABLE 67 FRANCE: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 93
TABLE 68 FRANCE: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET,
BY TYPE, 2018–2025 (USD MILLION) 94
TABLE 69 FRANCE: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 94
TABLE 70 FRANCE: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 94
10.3.4 ITALY 95
10.3.4.1 Italy is one of the leaders in life science research in Europe 95
TABLE 71 ITALY: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 95
TABLE 72 ITALY: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 95
TABLE 73 ITALY: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 96
TABLE 74 ITALY: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 96
10.3.5 SPAIN 96
10.3.5.1 Increasing opportunities for generics and biosimilars manufacturers to support market growth in Spain 96
TABLE 75 SPAIN: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 97
TABLE 76 SPAIN: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET,
BY TYPE, 2018–2025 (USD MILLION) 97
TABLE 77 SPAIN: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 97
TABLE 78 SPAIN: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 98
10.3.6 REST OF EUROPE 98
TABLE 79 ROE: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 98
TABLE 80 ROE: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 99
TABLE 81 ROE: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 99
TABLE 82 ROE: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 99

10.4 ASIA PACIFIC 100
FIGURE 25 APAC: MYCOPLASMA TESTING MARKET SNAPSHOT 101
TABLE 83 APAC: MYCOPLASMA TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 101
TABLE 84 APAC: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 102
TABLE 85 APAC: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 102
TABLE 86 APAC: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 102
TABLE 87 APAC: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 103
10.4.1 CHINA 103
10.4.1.1 China accounted for the largest share of the APAC market in 2019 103
TABLE 88 CHINA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 103
TABLE 89 CHINA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET,
BY TYPE, 2018–2025 (USD MILLION) 104
TABLE 90 CHINA: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 104
TABLE 91 CHINA: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 104
10.4.2 JAPAN 105
10.4.2.1 Increasing demand for technologically advanced research products to drive market growth in Japan 105
TABLE 92 JAPAN: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 105
TABLE 93 JAPAN: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET,
BY TYPE, 2018–2025 (USD MILLION) 106
TABLE 94 JAPAN: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 106
TABLE 95 JAPAN: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 106
10.4.3 INDIA 107
10.4.3.1 Growing CRO base in India to support market growth 107
TABLE 96 INDIA: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 107
TABLE 97 INDIA: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET,
BY TYPE, 2018–2025 (USD MILLION) 108
TABLE 98 INDIA: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 108
TABLE 99 INDIA: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 108
10.4.4 REST OF ASIA PACIFIC 109
TABLE 100 ROAPAC: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 109
TABLE 101 ROAPAC: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET,
BY TYPE, 2018–2025 (USD MILLION) 110
TABLE 102 ROAPAC: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 110
TABLE 103 ROAPAC: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 110
10.5 REST OF THE WORLD 111
TABLE 104 ROW: MYCOPLASMA TESTING MARKET, BY PRODUCT & SERVICE,
2018–2025 (USD MILLION) 112
TABLE 105 ROW: MYCOPLASMA TESTING ASSAYS, KITS, & REAGENTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 112
TABLE 106 ROW: MYCOPLASMA TESTING MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 112
TABLE 107 ROW: MYCOPLASMA TESTING MARKET, BY END USER,
2018–2025 (USD MILLION) 113
11 COMPETITIVE LANDSCAPE 114
11.1 OVERVIEW 114
FIGURE 26 KEY DEVELOPMENTS IN THE MYCOPLASMA TESTING MARKET
(JANUARY 2017–SEPTEMBER 2020) 114
11.2 MYCOPLASMA TESTING MARKET SHARE ANALYSIS 115
FIGURE 27 MYCOPLASMA TESTING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019 115
11.3 COMPANY EVALUATION QUADRANT 115
11.3.1 DEFINITION AND METHODOLOGY 115
11.3.2 VENDOR DIVE OVERVIEW 115
11.3.2.1 Stars 115
11.3.2.2 Emerging leaders 116
11.3.2.3 Pervasive 116
11.3.2.4 Participants 116
FIGURE 28 MYCOPLASMA TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 116
11.4 COMPETITIVE SCENARIO 117
11.4.1 PRODUCT/SERVICE LAUNCHES 117
TABLE 108 PRODUCT/SERVICE LAUNCHES & REGULATORY APPROVALS
(JANUARY 2017–SEPTEMBER 2020) 117
11.4.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 117
TABLE 109 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
(JANUARY 2017–SEPTEMBER 2020) 117
11.4.3 ACQUISITIONS 118
TABLE 110 ACQUISITIONS (JANUARY 2017–SEPTEMBER 2020) 118
11.4.4 EXPANSIONS 118
TABLE 111 EXPANSIONS (JANUARY 2017–SEPTEMBER 2020) 118

12 COMPANY PROFILES 119
12.1 KEY PLAYERS 119
(Business overview, Products offered, Recent developments, MNM view)*
12.1.1 MERCK KGAA 119
FIGURE 29 MERCK KGAA: COMPANY SNAPSHOT (2019) 119
12.1.2 ROCHE DIAGNOSTICS (A DIVISION OF F. HOFFMAN-LA ROCHE LTD.) 122
FIGURE 30 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019) 122
12.1.3 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 124
FIGURE 31 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2019) 124
12.1.4 LONZA GROUP LTD. 126
FIGURE 32 LONZA GROUP LTD.: COMPANY SNAPSHOT (2019) 126
12.1.5 THERMO FISHER SCIENTIFIC, INC. 128
FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019) 128
12.1.6 EUROFINS SCIENTIFIC GROUP 131
FIGURE 34 EUROFINS SCIENTIFIC GROUP: COMPANY SNAPSHOT (2019) 131
12.1.7 SARTORIUS STEDIM BIOTECH S.A. 132
FIGURE 35 SARTORIUS STEDIM BIOTECH S.A.: COMPANY SNAPSHOT (2019) 132
12.1.8 AGILENT TECHNOLOGIES, INC. 133
FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2019) 133
12.1.9 MERIDIAN BIOSCIENCE, INC. 134
FIGURE 37 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2019) 134
12.1.10 AMERICAN TYPE CULTURE COLLECTION 136
12.2 OTHER PLAYERS 137
12.2.1 BIONIQUE TESTING LABORATORIES, INC. 137
12.2.2 INVIVOGEN 138
12.2.3 PROMOCELL GMBH 139
12.2.4 BIOLOGICAL INDUSTRIES ISRAEL BEIT HAEMEK LTD. 140
12.2.5 CLONGEN LABORATORIES, LLC. 141
12.2.6 CREATIVE BIOARRAY 142
12.2.7 NELSON LABORATORIES FAIRFIELD, INC. (A PART OF SOTERA HEALTH) 143
12.2.8 NORGEN BIOTEK CORPORATION 144
12.2.9 BIOTOOLS B & M LABS, S.A. 144
12.2.10 GENBIO (A PART OF EXONHIT THERAPEUTICS SA) 145
12.2.11 GENECOPOEIA, INC. 145
12.2.12 MINERVA BIOLABS GMBH 146
12.2.13 MYCOPLASMA EXPERIENCE 146
12.2.14 SAVYON DIAGNOSTICS 147
12.2.15 SCIENCELL RESEARCH LABORATORIES 147
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX 148
13.1 DISCUSSION GUIDE 148
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 151
13.3 AVAILABLE CUSTOMIZATIONS 153
13.4 RELATED REPORTS 153
13.5 AUTHOR DETAILS 154



★調査レポート[マイコプラズマ検査の世界市場予測(~2025):製品・サービス別、技術別、用途別、エンドユーザー別、地域別] ( Mycoplasma Testing Market by Product & Service (Assays, Kits, Reagents), Technique (NAT, ELISA, Staining), Application (Cell Line, End of Production Testing), End User (Biopharmaceutical, Cell Banks, CROs), Region - Global Forecast to 2025 / BT 3371) 販売に関する免責事項
[マイコプラズマ検査の世界市場予測(~2025):製品・サービス別、技術別、用途別、エンドユーザー別、地域別] ( Mycoplasma Testing Market by Product & Service (Assays, Kits, Reagents), Technique (NAT, ELISA, Staining), Application (Cell Line, End of Production Testing), End User (Biopharmaceutical, Cell Banks, CROs), Region - Global Forecast to 2025 / BT 3371) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆